[Recovery from parkinsonism with N-acetylcysteine-differentiated neurons].
The upregulation of dopaminergic neuronal differentiation is necessary for stem cell therapy in Parkinson's disease (PD). In this study, neuronal differentiation efficiency increased by more than 2 times in P19 embryonic stem cells (ESCs) induced by N-acetylcysteine (NAC) and retinoic acid (RA) as compared to RA alone, with suppressed glial differentiation. The majority of NAC-treated stem cells grafted into brains of PD mice differentiated into dopaminergic neurons and persisted well for 6 weeks. Parkinsonism was also greatly improved after grafting NAC-treated cells in comparison to cells treated with only RA. Our results strongly suggest that NAC treatment may be an effective strategy for generating stem cells fated to become dopaminergic neurons for PD clinical therapy.
Y H
YH
Noh
J Y
JY
Kim
D H
DH
Kim
O H
OH
Kim
J
J
Park
B-S
BS
Kee
D-S
DS
Sohn
D
D
Kim
Y H
YH
Chung
K Y
KY
Kim
W B
WB
Lee
S S
SS
Kim
D000111:Acetylcysteine / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D053595:Embryonic Stem Cells / Q000187:drug effects*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000187:drug effects*; D020734:Parkinsonian Disorders / Q000473:pathology* / Q000628:therapy*; D033581:Stem Cell Transplantation; D014212:Tretinoin / Q000494:pharmacology
D014212:Tretinoin; D004298:Dopamine; D000111:Acetylcysteine